Recently, the team of Professor Li Xiaoying, director of the Department of Endocrinology, Zhongshan Hospital Affiliated to Fudan University and vice chairman of the Diabetes Branch of the Chinese Medical Association, based on the clinical experience of insulin use in diabetic patients, combined with machine learning technology, innovatively developed an artificial intelligence insulin-assisted decision-making system (iNCDSS), which has been successfully realized patent conversion.

This new invention will effectively solve the pain points encountered in the use of insulin for diabetic patients. It can be applied to multiple scenarios, including in-hospital blood glucose management. It can formulate accurate and individualized insulin treatment plans in a timely and effective manner and improve the blood glucose management level of diabetic patients.

The artificial intelligence insulin-assisted decision-making system is based on the electronic medical records of diabetic patients in the Endocrinology Department of Zhongshan Hospital. The application of artificial intelligence technology is established based on the clinical diagnosis and treatment experience of experts in the hospital's endocrinology department.

According to Li Xiaoying, the system uses expert experience as the framework to establish a real-world data machine learning model to maximize the restoration of the expert's insulin treatment strategy during the treatment of diabetic patients; the system also embeds the diagnosis and treatment model, automatically extracts the characteristics of the application population, and recommends treatment program in real-time.

Studies have shown that the accuracy of the system's recommended treatment plan is as high as 90%, which is better than the level of junior clinicians and reaches the level of endocrinology specialists.

According to Chief Physician Cheng Leilei, Chief Physician of the Patent Work of the Scientific Research Department of Zhongshan Hospital, this patent was applied for national invention patent authorization on April 17, 2019. It was successfully transferred on March 19 this year. After the industrialization realized, after clinical trials and registration of the product, it will be introduced to the domestic and foreign markets to benefit more diabetic patients.